Health Care • Biotechnology: Pharmaceutical Preparations
$2.47 ▼ -0.01
(-0.40%)
MKT CAP: $57.3M • VOL: 47.0K
52W L $1 52W H $3
ROARABLE / RQD
D- • 41/100
PIOTROSKI
3 / 9
BOLD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$63.6M | -$73.3M | -$54.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$58.2M | -$65.4M | -$49.4M |
| EBITDA (Normalized) | -$63.1M | -$71.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$46.7M | -$60.8M | -$46.9M |
| Capital Expenditures (CapEx) | $546.0K | $2.5M | — |
| Free Cash Flow (FCF) | -$47.2M | -$63.4M | -$46.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $17.9M | $26.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $98.7M | $150.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BOLD.